Translator Disclaimer
31 March 2009 Europium doped Gd2O3 and FeCo nanoparticles for biomedical application
Author Affiliations +
Abstract
Nanometer-sized particles have novel optical, electronic, magnetic or structural properties and are currently under intense development for application in cancer, cardiovascular diseases, and degenerative neurological disorders such as alzheimer's disease. Targeted nanoparticle drugs offer significant advantages in improving cancer therapeutic efficacy and simultaneously reducing drug toxicity. We report here the synthesis, characterization and toxicity test of FeCo and Eu: Gd2O3 nanoparticles. Chemical routes, such ad coprecipitation and sol-gel techniques were used for the synthesis of the nanoparticles, and the surface of the nanoparticles was coated with silica. Structural and microstructural studies reveal that both type of nanoparticles 20 nm in size with very narrow size distribution. These nanoparticles demonstrate strong magnetic and optical properties at room temperature. Toxicity test shows that FeCo nanoparticles are very toxic, however toxicity decreases when the nanoparticles were coated with a thin layer of silica. However toxicity decreases when the nanoparticles were coated with a thin layer of silica. However, both uncoated and coated Eu:Gd2O3 nanoparticles show significantly reduced toxicity. Our results suggest that these nanoparticles are useful for biomedical applications. The detail of the results will be presented.
© (2009) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
K. Zhang, T. Holloway, M. Bahoura, A. K. Pradhan, R. Prabakaran, J. Pradhan, S. Smith, J. C. Hall, G. T. Ramesh, D. R. Sahu, and J.-L. Huang "Europium doped Gd2O3 and FeCo nanoparticles for biomedical application", Proc. SPIE 7291, Nanosensors, Biosensors, and Info-Tech Sensors and Systems 2009, 729104 (31 March 2009); https://doi.org/10.1117/12.817306
PROCEEDINGS
10 PAGES


SHARE
Advertisement
Advertisement
Back to Top